IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

Acute myeloid leukemia (AML) is a heterogeneous disease. Even within the same NPM1-mutated genetic subgroup, some patients harbor additional mutations in FLT3, IDH1/2, DNMT3A or TET2. Recent studies have shown the prognostic significance of minimal residual disease (MRD) in AML but it remains to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Debarri, Houria, Lebon, Delphine, Roumier, Christophe, Cheok, Meyling, Marceau-Renaut, Alice, Nibourel, Olivier, Geffroy, Sandrine, Helevaut, Nathalie, Rousselot, Philippe, Gruson, Bérengère, Gardin, Claude, Chretien, Marie-Lorraine, Sebda, Shéhérazade, Figeac, Martin, Berthon, Céline, Quesnel, Bruno, Boissel, Nicolas, Castaigne, Sylvie, Dombret, Hervé, Renneville, Aline, Preudhomme, Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747230/
https://www.ncbi.nlm.nih.gov/pubmed/26486081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747230/
https://www.ncbi.nlm.nih.gov/pubmed/26486081

Ejemplares similares